Seres Therapeutics
Yahoo Finance • 8 months ago
11 Oversold NASDAQ Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now. NASDAQ Leads Th... Full story
Yahoo Finance • 12 months ago
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62%
Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to their trading decisions The top 5 shareholders own 52% of the company Ownership research along with analyst forecasts... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Seres Therapeutics, Inc. (NASDAQ: MCRB) and Encourages Investors to Contact the Firm
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Seres Therapeutics, Inc. (NASDAQ: MCRB) (“Seres”) on behalf of the company’s investors. Since June 2023, shares of Seres’ common stock ha... Full story
Yahoo Finance • last year
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Seres Therapeutics, Inc.; Urges Seres Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether... Full story
Yahoo Finance • 2 years ago
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship, Metaphore has built a first-in... Full story
Yahoo Finance • 2 years ago
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Thank you for holding, and welcome everyone, to the Seres Therapeutics Fourth Quarter 2022 Conference Call. . Thank you. I will now turn the c... Full story
Yahoo Finance • 2 years ago
Q4 2022 Seres Therapeutics Inc Earnings Call
Participants Carlo Tanzi; IR Officer; Seres Therapeutics, Inc. David A. Arkowitz; Executive VP, CFO & Head of Business Development; Seres Therapeutics, Inc. David S. Ege; Executive VP & CTO; Seres Therapeutics, Inc. Eric D. Shaff; Pres... Full story
Yahoo Finance • 2 years ago
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
– SER-109 Biologics License Application (BLA) under review with U.S. Food and Drug Administration (FDA) with target action date of April 26, 2023 under Prescription Drug User Fee Act (PDUFA) – – Anticipate SER-109 commercial launch soon a... Full story
Yahoo Finance • 2 years ago
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
CAMBRIDGE, Mass., February 28, 2023--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 a... Full story
Yahoo Finance • 2 years ago
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets WILMINGTON, Mass. & CAMBRIDGE, Mass., February 16, 2023--(BUSINESS WIRE)--Charles River Laboratories Internation... Full story
Yahoo Finance • 2 years ago
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
– Renowned investigator in microbial genomics to joinSeres to advance Company’s efforts to develop novel microbiome therapeutics – – Following successful Data Safety Monitoring Board meeting in December for SER-155 Cohort 1, enrollment of... Full story
Yahoo Finance • 2 years ago
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
– Summarized data from the study's secondary endpoints show investigational oral microbiome therapeutic rapidly and durably lowered risk of recurrent C. difficile infection – CAMBRIDGE, Mass., October 19, 2022--(BUSINESS WIRE)--Seres Ther... Full story
Yahoo Finance • 2 years ago
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
– Clinical and preclinical data support Seres’ development of microbiome therapeutics to reduce the incidence of antibiotic-resistant bacterial infections – CAMBRIDGE, Mass., September 08, 2022--(BUSINESS WIRE)--Seres Therapeutics, Inc. (... Full story
Yahoo Finance • 2 years ago
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
– Investigational therapeutic SER-109 has the potential to become the first-ever FDA-approved oral microbiome therapeutic – – Anticipated product launch in the first half of 2023 – CAMBRIDGE, Mass., September 07, 2022--(BUSINESS WIRE)--S... Full story
Yahoo Finance • 2 years ago
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
– ECOSPOR IV study shows favorable safety profile through 24-week follow-up, consistent with the safety profile observed in ECOSPOR III study – 91.3% sustained clinical response achieved at eight weeks in overall population with consisten... Full story
Yahoo Finance • 3 years ago
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharm... Full story
